Tissue Regeneration Contributing Large Share In The Acellular Dermal Matrices Market

 Acellular Dermal Matrices Market

The Acellular Dermal Matrices Market is estimated to be valued at US$ 8.8 Bn in 2023 and is expected to exhibit a CAGR of 12.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Acellular dermal matrices are processed cadaveric acellular dermal matrices used for soft tissue reinforcement and replacement in plastic and reconstructive surgeries such as breast reconstruction and hernia repair. They offer advantages such as biocompatibility, biodegradability, cost-effectiveness and lower risk of rejection or infection compared to autologous dermal grafts. The products fill voids, facilitate wound healing and provide matrix for neovascularization and tissue integration.

Market key trends:

One of the major trends driving the growth of the acellular dermal matrices market is the increased usage of these products in soft tissue repair procedures. According to the American Society for Aesthetic Plastic Surgery, nearly 313,735 breast reconstruction procedures were performed in the United States in 2021. Acellular dermal matrices are widely used in breast reconstruction to fill the voids under the skin flaps and provide scaffold for tissue regeneration. Furthermore, hernia repair surgery market is also growing rapidly, especially in developing countries, owing to rising geriatric population and lifestyle diseases. Acellular dermal matrices help reinforce the thin abdominal wall tissue and prevent recurrence of hernia. Their versatile applications along with soft tissue repair benefits will continue fueling the demand over the forecast period.

Porter's Analysis

Threat of new entrants: Low capital requirement for starting acellular dermal matrices manufacturing limits the threat of new entrants. However, established suppliers have significant brand recognition and distribution networks.

Bargaining power of buyers: Large group purchasing organizations and integrated healthcare systems have significant bargaining power over suppliers in the market.

Bargaining power of suppliers: A few major companies dominate the supply of acellular dermal matrices, giving them strong bargaining power over buyers.

Threat of new substitutes: Ongoing research has potential to develop new regenerative matrices that could substitute acellular dermal matrices.

Competitive rivalry: Intense competition exists between major suppliers to gain market share.

SWOT Analysis

Strengths: Growing demand for reconstructive surgeries and advancement in tissue engineering drive the Acellular Dermal Matrices Market growth.

Weaknesses: High production cost and lack of skilled professionals restrict the market growth.

Opportunities: Untapped developing markets and ongoing R&D in tissue regeneration present new opportunities.

Threats: Stringent regulatory approval process and reimbursement issues challenge the market.

Key Takeaways

The global acellular dermal matrices market is expected to witness high growth at a CAGR of 12.1% over the forecast period due to rising incidence of breast reconstruction surgeries.

The US market holds the highest share and is expected to retain its dominance over the forecast period. Growing awareness about cosmetic breast reconstruction surgeries drives the US market.

The Asia Pacific region is anticipated to exhibit the fastest growth over 2023-2030. Increasing healthcare expenditure and medical tourism in countries like China, India promotes the regional market growth.

Key players operating in the acellular dermal matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.

Read More : https://www.marketwebjournal.com/acellular-dermal-matrices-market-opportunities-analysis-size-share/